Using SleepImage to detect respiratory failure in people with ALS
Official title: Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis
Run by Royal Brompton & Harefield NHS Foundation Trust · NCT07502677 · Data updated 2026-11-12
This project will try SleepImage monitoring during an overnight sleep recording to see if it can detect early respiratory failure in adults with ALS.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | March 24, 2026 |
| Main results expected | September 1, 2026 |
| Study ends | March 24, 2027 |
| Registry record updated | March 31, 2026 |
| Trial ID | NCT07502677 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a neurologist-confirmed diagnosis of ALS who are not currently using NIV, do not have known respiratory or unstable cardiac disease, and can give informed consent are the ideal candidates.
✕Probably not a fit
Patients already on NIV, those with known respiratory disease or unstable cardiac conditions, or those unable to give informed consent (for example due to frontotemporal dementia) are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects SleepImage recordings during participants' routine overnight sleep tests and compares those signals to the standard respiratory data collected at the visit. SleepImage uses tonometry and cardiopulmonary coupling (CPC) analysis to characterize stable versus unstable sleep and breathing patterns in addition to pulse oximetry. Researchers will compare SleepImage-derived markers of breathing instability against existing clinical and physiological measures to determine diagnostic accuracy for impending respiratory failure. The goal is to identify whether SleepImage can provide an earlier or more sensitive signal than peripheral oxygen measures alone to guide timing of noninvasive ventilation.
Why it matters
Potential benefit: If successful, SleepImage could provide earlier, noninvasive warning of respiratory failure so clinicians can start breathing support at a more appropriate time.
How similar studies have gone: SleepImage and cardiopulmonary coupling approaches are FDA-cleared for sleep analysis and have shown promise in detecting breathing instability, but applying them specifically to time NIV initiation in ALS is relatively novel with limited prior validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 and over with a Neurologist confirmed diagnosis of ALS Exclusion Criteria: * Patients with known respiratory disease * Unstable cardiac disease, stable hypertension or ischaemic heart disease * Current NIV use * Inability to give consent (expected \~15% due to frontotemporal dementia)
Where it's running
-
Royal Brompton Hospital
London, United Kingdom Recruiting
Study contacts
- Study coordinator: Professor Michael Polkey
- Email: mike.polkey@nhs.net
- Phone: 020 7352 8121
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Implanted Brain-Computer Interface to Help People with Severe Arm Impairment
We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.
-
Brain-computer interface chat tool for people with ALS
This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.
-
BIIB147 safety and how it behaves in adults with ALS
This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.
-
Aims to restore UNC13A function in people with ALS
This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.
-
LTX-002 in adults with ALS
A study will test whether the experimental drug LTX-002 is safe and tolerable in adults with ALS and see how the body handles the drug and how it affects ALS indicators.
-
Repeated ultrasound-assisted blood-brain barrier opening in ALS
This trial tests whether repeatedly opening the blood-brain barrier with ultrasound is safe and may help people with ALS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.